Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary Welch

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Current Treatment Options in Neurology|June 16, 2009
Glioblastoma multiformeMary Welch, Rose Lai
Molecular Microbiology|September 6, 2007
Mycoplasma genitalium: an efficient strategy to generate genetic variation from a minimal genomeLiang Ma, Jørgen S Jensen, Leann Myers, et al.
Anti-Cancer Drugs|March 12, 2004
Phase I trial of sequential raltitrexed followed by bolus 5-fluorouracil in patients with advanced colorectal cancerGary K Schwartz, Joseph Bertino, Nancy Kemeny, et al.
Acta Neuropathologica Communications|April 28, 2022
Thoracic low grade glial neoplasm with concurrent H3 K27M and PTPN11 mutationsMichael G Argenziano, Julia L Furnari, Michael L Miller, et al.
Journal of Electrocardiology|September 14, 2010
Paramedics as decision makers on the activation of the catheterization laboratory in the presence of acute ST-elevation myocardial infarctionDwayne R Young, Marc Murinson, Charles Wilson, et al.
Bioorganic & Medicinal Chemistry Letters|August 25, 2004
Rational design of 6-methylsulfonylindoles as selective cyclooxygenase-2 inhibitorsJeffrey A Campbell, Viola Bordunov, Chris A Broka, et al.
AJNR. American Journal of Neuroradiology|February 23, 2026
[68Ga]-DOTATATE PET SUV Reduction After Bevacizumab in High-Grade Meningioma: A Potential Treatment Response BiomarkerKellen Vo Vu, Hannah G Otis, Andrew Brandmaier, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 9, 2008
Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivityRonald J Hill, Karim Dabbagh, Deborah Phippard, et al.
Neuro-Oncology|April 6, 2021
Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experienceEudocia Q Lee, Wendy Selig, Clair Meehan, et al.
Journal of Medicinal Chemistry|October 17, 2003
Design and synthesis of 4-azaindoles as inhibitors of p38 MAP kinaseAlejandra Trejo, Humberto Arzeno, Michelle Browner, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Current Treatment Options in Neurology|June 16, 2009
Glioblastoma multiformeMary Welch, Rose Lai
Molecular Microbiology|September 6, 2007
Mycoplasma genitalium: an efficient strategy to generate genetic variation from a minimal genomeLiang Ma, Jørgen S Jensen, Leann Myers, et al.
Anti-Cancer Drugs|March 12, 2004
Phase I trial of sequential raltitrexed followed by bolus 5-fluorouracil in patients with advanced colorectal cancerGary K Schwartz, Joseph Bertino, Nancy Kemeny, et al.
Acta Neuropathologica Communications|April 28, 2022
Thoracic low grade glial neoplasm with concurrent H3 K27M and PTPN11 mutationsMichael G Argenziano, Julia L Furnari, Michael L Miller, et al.
Journal of Electrocardiology|September 14, 2010
Paramedics as decision makers on the activation of the catheterization laboratory in the presence of acute ST-elevation myocardial infarctionDwayne R Young, Marc Murinson, Charles Wilson, et al.
Bioorganic & Medicinal Chemistry Letters|August 25, 2004
Rational design of 6-methylsulfonylindoles as selective cyclooxygenase-2 inhibitorsJeffrey A Campbell, Viola Bordunov, Chris A Broka, et al.
AJNR. American Journal of Neuroradiology|February 23, 2026
[68Ga]-DOTATATE PET SUV Reduction After Bevacizumab in High-Grade Meningioma: A Potential Treatment Response BiomarkerKellen Vo Vu, Hannah G Otis, Andrew Brandmaier, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 9, 2008
Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivityRonald J Hill, Karim Dabbagh, Deborah Phippard, et al.
Neuro-Oncology|April 6, 2021
Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experienceEudocia Q Lee, Wendy Selig, Clair Meehan, et al.
Journal of Medicinal Chemistry|October 17, 2003
Design and synthesis of 4-azaindoles as inhibitors of p38 MAP kinaseAlejandra Trejo, Humberto Arzeno, Michelle Browner, et al.
Pageof 2